Moreover, DNMT inhibitors, including RG108, 5‐azacytidine (5‐aza‐dC), and zebularine, reportedly suppress the survival of various types of cancer cells (Brueckner et al, 2005; Yang et al, 2013; Gayet et al, 2015), and 5‐aza‐dC has indeed been widely used for treating myelodysplastic syndromes (MDS; Fenaux et al, 2009; Gore et al, 2013). This evidence concerns the gene DNMT1 and myelodysplastic syndrome.